ATE338553T1 - Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin - Google Patents

Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin

Info

Publication number
ATE338553T1
ATE338553T1 AT98906594T AT98906594T ATE338553T1 AT E338553 T1 ATE338553 T1 AT E338553T1 AT 98906594 T AT98906594 T AT 98906594T AT 98906594 T AT98906594 T AT 98906594T AT E338553 T1 ATE338553 T1 AT E338553T1
Authority
AT
Austria
Prior art keywords
benzotriazine
paclitaxel
dioxide
amino
mammal
Prior art date
Application number
AT98906594T
Other languages
English (en)
Inventor
Daniel L Dexter
Paul E Juniewicz
James B Rake
Hoff Daniel D Von
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Application granted granted Critical
Publication of ATE338553T1 publication Critical patent/ATE338553T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98906594T 1997-03-07 1998-02-17 Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin ATE338553T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81476997A 1997-03-07 1997-03-07

Publications (1)

Publication Number Publication Date
ATE338553T1 true ATE338553T1 (de) 2006-09-15

Family

ID=25215967

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906594T ATE338553T1 (de) 1997-03-07 1998-02-17 Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin

Country Status (15)

Country Link
US (2) US6063780A (de)
EP (1) EP1014990B1 (de)
JP (1) JP2001513110A (de)
AT (1) ATE338553T1 (de)
AU (1) AU6178198A (de)
BR (1) BR9808221A (de)
CA (1) CA2281807C (de)
DE (1) DE69835824T2 (de)
DK (1) DK1014990T3 (de)
ES (1) ES2268764T3 (de)
HR (1) HRP980095A2 (de)
NO (1) NO324974B1 (de)
PT (1) PT1014990E (de)
WO (1) WO1998039009A1 (de)
ZA (1) ZA981609B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1014990B1 (de) * 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
WO2000021527A2 (fr) 1998-10-14 2000-04-20 Debiopharm S.A. Conditionnement d'une preparation d'oxaliplatine
DE19925211B4 (de) * 1999-06-01 2006-01-12 PBS Pharmaceutical Bulk Substances SA Kit zur Herstellung einer Formulierung von Paclitaxel
BRPI0013613B8 (pt) * 1999-08-30 2021-05-25 Debiopharm Sa composição farmacêuticamente estável de oxaliplatina para administração parenteral.
US7070796B1 (en) 1999-08-30 2006-07-04 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation for parenteral administration
US7012072B2 (en) 2000-12-12 2006-03-14 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
WO2004012746A2 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
AU2003239511A1 (en) * 2003-05-20 2004-12-13 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US20060275331A1 (en) * 2004-08-31 2006-12-07 Borek Zaludek Pharmaceutical composition, method of manufacturing and therapeutic use thereof
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090136521A1 (en) * 2005-10-03 2009-05-28 Genetix Pharmaceuticals , Inc. Method for Selectively Depleting Hypoxic Cells
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
US8026017B2 (en) 2007-03-16 2011-09-27 The United States Of America As Represented By The Secretary Of The Army High voltage methanol fuel cell assembly using proton exchange membranes and base/acid electrolytes
WO2009126705A2 (en) 2008-04-10 2009-10-15 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP4201403A1 (de) * 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Verbindungen tirapazamin und quazinon zur verwendung bei der behandlung von gm2-gangliosidosen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
EP1014990B1 (de) * 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin

Also Published As

Publication number Publication date
EP1014990A4 (de) 2004-03-24
HRP980095A2 (en) 1998-12-31
CA2281807C (en) 2007-10-16
US6319923B1 (en) 2001-11-20
DE69835824T2 (de) 2007-03-29
ES2268764T3 (es) 2007-03-16
CA2281807A1 (en) 1998-09-11
EP1014990A1 (de) 2000-07-05
ZA981609B (en) 1998-12-08
PT1014990E (pt) 2006-11-30
DK1014990T3 (da) 2006-12-11
JP2001513110A (ja) 2001-08-28
AU6178198A (en) 1998-09-22
US6063780A (en) 2000-05-16
NO324974B1 (no) 2008-01-14
BR9808221A (pt) 2000-05-16
NO994330L (no) 1999-10-25
NO994330D0 (no) 1999-09-06
WO1998039009A1 (en) 1998-09-11
EP1014990B1 (de) 2006-09-06
DE69835824D1 (de) 2006-10-19

Similar Documents

Publication Publication Date Title
ATE338553T1 (de) Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin
EP1068870A4 (de) Antitumorale mittel
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
DE59709437D1 (de) Neue phenanthridine
ATE386808T1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
DE69426423D1 (de) NEUE HEMMER VON URIDINPHOSPHORYLASE (UrdPase) UND DIHYDROURACILDEHYDROGENASE (DHUDase)
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
WO1999011256A8 (fr) L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
ATE204476T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
DE69426986D1 (de) Behandlung von laminitis
RU94024337A (ru) Антиметастатическое средство
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1014990

Country of ref document: EP

REN Ceased due to non-payment of the annual fee